U.S. markets open in 8 hours 23 minutes
  • S&P Futures

    4,220.00
    +10.00 (+0.24%)
     
  • Dow Futures

    33,348.00
    +88.00 (+0.26%)
     
  • Nasdaq Futures

    13,438.50
    +46.50 (+0.35%)
     
  • Russell 2000 Futures

    1,975.00
    +5.50 (+0.28%)
     
  • Crude Oil

    91.57
    -0.36 (-0.39%)
     
  • Gold

    1,800.50
    -13.20 (-0.73%)
     
  • Silver

    20.43
    -0.31 (-1.48%)
     
  • EUR/USD

    1.0286
    -0.0016 (-0.15%)
     
  • 10-Yr Bond

    2.7860
    0.0000 (0.00%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2190
    -0.0028 (-0.23%)
     
  • USD/JPY

    133.1480
    +0.2750 (+0.21%)
     
  • BTC-USD

    24,470.82
    +1,506.16 (+6.56%)
     
  • CMC Crypto 200

    576.64
    +45.42 (+8.55%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Conference call and webcast to be held at 4:30 p.m. EDT

NEW HAVEN, Conn., Aug. 4, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis (IPF), today announced that management will host a conference call and live audio webcast on Thursday, August 11, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the second quarter ended June 30, 2022.

Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)
Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)

Trevi Therapeutics will host a conference call on August 11 to review Q2 2022 financial results

To participate in the live conference call by phone, please dial (888) 317 6003 (domestic) or (412) 317 6061 (international) and provide access code 9437525. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio for the treatment of prurigo nodularis and chronic cough in adults with idiopathic pulmonary fibrosis. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

About Haduvio

Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed ĸ-opioid receptor agonist and µ-opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The ĸ- and µ-opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with µ-opioid agonists because it antagonizes, or blocks, µ-opioid receptors. Parenteral nalbuphine is not currently scheduled as a controlled substance by the DEA in the United States or by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Nalbuphine ER has been granted Fast Track designation by the FDA for the treatment of itch in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q2-2022-financial-results-and-provide-a-corporate-update-on-august-11-2022-301600493.html

SOURCE Trevi Therapeutics, Inc.